Colony Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $14.1M | Sell |
423,892
-12,354
| -3% | -$437K | 0.21% | 115 |
|
|
2023
Q2 | $16M | Sell |
436,246
-9,794
| -2% | -$381K | 0.23% | 114 |
|
|
2023
Q1 | $18.2M | Buy |
446,040
+84,456
| +23% | +$3.65M | 0.27% | 97 |
|
|
2022
Q4 | $18.5M | Buy |
361,584
+29,952
| +9% | +$1.44M | 0.26% | 103 |
|
|
2022
Q3 | $14.5M | Buy |
331,632
+3,335
| +1% | +$162K | 0.26% | 101 |
|
|
2022
Q2 | $17.2M | Buy |
328,297
+39,787
| +14% | +$2.03M | 0.3% | 82 |
|
|
2022
Q1 | $14.9M | Buy |
288,510
+140,655
| +95% | +$7.3M | 0.22% | 108 |
|
|
2021
Q4 | $8.73M | Buy |
147,855
+5,367
| +4% | +$266K | 0.15% | 118 |
|
|
2021
Q3 | $6.13M | Buy |
142,488
+72,892
| +105% | +$3.23M | 0.12% | 151 |
|
|
2021
Q2 | $2.73M | Sell |
69,596
-68,495
| -50% | -$2.66M | 0.05% | 265 |
|
|
2021
Q1 | $5M | Sell |
138,091
-39,594
| -22% | -$1.41M | 0.11% | 178 |
|
|
2020
Q4 | $6.54M | Sell |
177,685
-18,170
| -9% | -$666K | 0.15% | 129 |
|
|
2020
Q3 | $6.82M | Buy |
195,855
+55,168
| +39% | +$1.93M | 0.18% | 117 |
|
|
2020
Q2 | $4.37M | Sell |
140,687
-470
| -0.3% | -$16K | 0.13% | 158 |
|
|
2020
Q1 | $4.37M | Sell |
141,157
-149,791
| -51% | -$5.1M | 0.14% | 155 |
|
|
2019
Q4 | $10.8M | Sell |
290,948
-385,918
| -57% | -$13.7M | 0.27% | 97 |
|
|
2019
Q3 | $23.1M | Sell |
676,866
-93,514
| -12% | -$3.4M | 0.73% | 33 |
|
|
2019
Q2 | $31.7M | Buy |
770,380
+285,865
| +59% | +$11.4M | 1% | 17 |
|
|
2019
Q1 | $19.5M | Buy |
484,515
+74,347
| +18% | +$2.98M | 0.82% | 29 |
|
|
2018
Q4 | $17M | Buy |
410,168
+348,090
| +561% | +$14.4M | 0.82% | 32 |
|
|
2018
Q3 | $2.6M | Buy |
62,078
+255
| +0.4% | +$9.82K | 0.13% | 150 |
|
|
2018
Q2 | $2.13M | Sell |
61,823
-3,546
| -5% | -$121K | 0.11% | 176 |
|
|
2018
Q1 | $2.2M | Buy |
65,369
+38,172
| +140% | +$1.31M | 0.12% | 173 |
|
|
2017
Q4 | $935K | Buy |
27,197
+4,499
| +20% | +$153K | 0.06% | 248 |
|
|
2017
Q3 | $769K | Sell |
22,698
-4,277
| -16% | -$137K | 0.05% | 245 |
|
|
2017
Q2 | $860K | Buy |
+26,975
| New | +$851K | 0.06% | 236 |
|
|
2017
Q1 | – | Sell |
-7,405
| Closed | -$228K | – | 292 |
|
|
2016
Q4 | $228K | Sell |
7,405
-227
| -3% | -$6.93K | 0.02% | 260 |
|
|
2016
Q3 | $245K | Sell |
7,632
-1,717
| -18% | -$57.4K | 0.03% | 233 |
|
|
2016
Q2 | $312K | Sell |
9,349
-481
| -5% | -$15.4K | 0.03% | 198 |
|
|
2016
Q1 | $276K | Buy |
9,830
+1,318
| +15% | +$37.6K | 0.03% | 209 |
|
|
2015
Q4 | $261K | Sell |
8,512
-897
| -10% | -$28.2K | 0.02% | 330 |
|
|
2015
Q3 | $280K | Buy |
9,409
+2,718
| +41% | +$87.1K | 0.03% | 291 |
|
|
2015
Q2 | $213K | Sell |
6,691
-7,423
| -53% | -$242K | 0.02% | 338 |
|
|
2015
Q1 | $466K | Buy |
14,114
+9,005
| +176% | +$286K | 0.05% | 225 |
|
|
2014
Q4 | $151K | Buy |
5,109
+199
| +4% | +$5.71K | 0.02% | 356 |
|
|
2014
Q3 | $138K | Buy |
4,910
+176
| +4% | +$4.94K | 0.02% | 343 |
|
|
2014
Q2 | $133K | Sell |
4,734
-832
| -15% | -$23.7K | 0.02% | 248 |
|
|
2014
Q1 | $170K | Buy |
5,566
+875
| +19% | +$26.1K | 0.02% | 225 |
|
|
2013
Q4 | $136K | Buy |
+4,691
| New | +$137K | 0.02% | 244 |
|
Other funds holding PFE
Colony Group's PFE Position: Q3 2023 in Review
Colony Group reduced its Pfizer (PFE) stake by 2.8% in Q3 2023, selling an estimated $437K and leaving 423,892 shares worth $14.1M. The position accounts for 0.21% of the portfolio, ranked #115.
Colony Group first reported a position in PFE in Q4 2013 and has held it in 39 quarters since. The position peaked at $31.7M in Q2 2019. 2,925 funds tracked by Wall St. Rank hold PFE as of Q3 2023.
- Colony Group held 423,892 shares of Pfizer worth $14.1M as of Q3 2023.
- Colony Group sold 12,354 Pfizer shares in Q3 2023, an estimated $437K.
- Pfizer made up 0.21% of Colony Group's portfolio in Q3 2023, its #115 holding.
- Colony Group first reported a position in Pfizer in Q4 2013 and has held it in 39 quarters since.
- Colony Group's Pfizer position peaked at $31.7M in Q2 2019.
- 2,925 funds tracked by Wall St. Rank held Pfizer as of Q3 2023.
Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.